Wall Street analysts forecast that Hologic, Inc. (NASDAQ:HOLX) will report sales of $781.53 million for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Hologic’s earnings, with estimates ranging from $776.89 million to $784.30 million. Hologic reported sales of $734.40 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.4%. The company is expected to issue its next earnings results on Wednesday, February 7th.
According to Zacks, analysts expect that Hologic will report full year sales of $781.53 million for the current fiscal year, with estimates ranging from $3.23 billion to $3.34 billion. For the next year, analysts expect that the business will report sales of $3.41 billion per share, with estimates ranging from $3.37 billion to $3.45 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Hologic.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $802.90 million during the quarter, compared to analysts’ expectations of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.52 earnings per share.
In related news, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,833 shares of company stock worth $1,107,270. Corporate insiders own 0.79% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HOLX. Grove Bank & Trust raised its holdings in Hologic by 115.8% during the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 1,535 shares in the last quarter. Hall Laurie J Trustee raised its holdings in Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares in the last quarter. Commonwealth Bank of Australia raised its holdings in Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 600 shares in the last quarter. MPS Loria Financial Planners LLC bought a new stake in Hologic during the second quarter worth about $191,000. Finally, National Asset Management Inc. bought a new stake in Hologic during the second quarter worth about $203,000. Institutional investors and hedge funds own 97.67% of the company’s stock.
Hologic (HOLX) opened at $43.37 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. The firm has a market capitalization of $11,923.32, a PE ratio of 21.41, a price-to-earnings-growth ratio of 2.09 and a beta of 0.95. Hologic has a twelve month low of $35.76 and a twelve month high of $46.80.
TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/23/hologic-inc-holx-expected-to-announce-quarterly-sales-of-781-53-million.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.